Literature DB >> 8219250

Action of "pure" antiestrogens in inhibiting estrogen receptor action.

M G Parker1.   

Abstract

The mechanism of action of the pure antiestrogens ICI 164384 and ICI 182780 has been investigated. Both antagonists are steroidal antiestrogens with 7 alpha-alkylamide side-chains. The antiestrogens reduce the cellular content of the estrogen receptor by reducing the half-life of the protein. A potential mechanism for this effect is suggested by the observation that the DNA binding activity of receptors which have been over-expressed in cells was inhibited in vitro. The inhibitory activity of analogues of ICI 164384 with different side chain lengths correlates with their ability to function as pure antiestrogens in vivo. Since the estrogen binding site overlaps with residues involved in dimerisation, the antiestrogens are likely to bind to a similar site and may therefore with receptor dimerisation in the hormone binding domain by means of the 7 alpha side-chain. We propose that the increased turnover of the receptor in the presence of ICI 164384 and ICI 182380 is a consequence of impaired dimerisation of the proteins.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8219250     DOI: 10.1007/bf00689686

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  38 in total

1.  Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor.

Authors:  S E Fawell; J A Lees; R White; M G Parker
Journal:  Cell       Date:  1990-03-23       Impact factor: 41.582

2.  The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function.

Authors:  N J Webster; S Green; J R Jin; P Chambon
Journal:  Cell       Date:  1988-07-15       Impact factor: 41.582

3.  Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction.

Authors:  H F Yang-Yen; J C Chambard; Y L Sun; T Smeal; T J Schmidt; J Drouin; M Karin
Journal:  Cell       Date:  1990-09-21       Impact factor: 41.582

4.  P59, an hsp 90-binding protein. Cloning and sequencing of its cDNA and preparation of a peptide-directed polyclonal antibody.

Authors:  M C Lebeau; N Massol; J Herrick; L E Faber; J M Renoir; C Radanyi; E E Baulieu
Journal:  J Biol Chem       Date:  1992-03-05       Impact factor: 5.157

5.  The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer.

Authors:  V Kumar; P Chambon
Journal:  Cell       Date:  1988-10-07       Impact factor: 41.582

6.  A potent specific pure antiestrogen with clinical potential.

Authors:  A E Wakeling; M Dukes; J Bowler
Journal:  Cancer Res       Date:  1991-08-01       Impact factor: 12.701

7.  Structural differences between the hormone and antihormone estrogen receptor complexes bound to the hormone response element.

Authors:  M Sabbah; F Gouilleux; B Sola; G Redeuilh; E E Baulieu
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-15       Impact factor: 11.205

8.  Human estrogen receptor mutants with altered estrogen and antiestrogen ligand discrimination.

Authors:  F Pakdel; B S Katzenellenbogen
Journal:  J Biol Chem       Date:  1992-02-15       Impact factor: 5.157

Review 9.  The steroid and thyroid hormone receptor superfamily.

Authors:  R M Evans
Journal:  Science       Date:  1988-05-13       Impact factor: 47.728

10.  Cell-specific inhibitory and stimulatory effects of Fos and Jun on transcription activation by nuclear receptors.

Authors:  L Shemshedini; R Knauthe; P Sassone-Corsi; A Pornon; H Gronemeyer
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

View more
  20 in total

1.  Effects of experimental chemoendocrine therapy with a combination of a pure antiestrogen and 5-fluorouracil on human breast cancer cells implanted in nude mice.

Authors:  Y Ogasawara; H Doihara; K Shiroma; Y Kanaya; N Shimizu
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

2.  Responsiveness to hormone, growth factor and drug treatment of a human breast cancer cell line: comparison between early and late cultures.

Authors:  A de Cupis; P Pirani; L Fazzuoli; R E Favoni
Journal:  In Vitro Cell Dev Biol Anim       Date:  1998 Nov-Dec       Impact factor: 2.416

3.  BRCA1-mimetic compound NSC35446.HCl inhibits IKKB expression by reducing estrogen receptor-α occupancy in the IKKB promoter and inhibits NF-κB activity in antiestrogen-resistant human breast cancer cells.

Authors:  Shyam Nathan; Yongxian Ma; York A Tomita; Eliseu De Oliveira; Milton L Brown; Eliot M Rosen
Journal:  Breast Cancer Res Treat       Date:  2017-08-14       Impact factor: 4.872

4.  Estrogen receptors mediate estradiol's effect on sensitization and CPP to cocaine in female rats: role of contextual cues.

Authors:  Annabell C Segarra; Yvonne M Torres-Díaz; Richard D Silva; Anabel Puig-Ramos; Raissa Menéndez-Delmestre; José G Rivera-Bermúdez; Waldo Amadeo; José L Agosto-Rivera
Journal:  Horm Behav       Date:  2013-12-17       Impact factor: 3.587

Review 5.  Mechanisms of tamoxifen resistance.

Authors:  C K Osborne; S A Fuqua
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

6.  Flexible small molecular anti-estrogens with N,N-dialkylated-2,5-diethoxy-4-morpholinoaniline scaffold targets multiple estrogen receptor conformations.

Authors:  Bethany K Asare; Emmanuel Yawson; Rajendram V Rajnarayanan
Journal:  Cell Cycle       Date:  2017-07-19       Impact factor: 4.534

7.  A robotic MCF-7:WS8 cell proliferation assay to detect agonist and antagonist estrogenic activity.

Authors:  Chun Z Yang; Warren Casey; Matthew A Stoner; Gayathri J Kollessery; Amy W Wong; George D Bittner
Journal:  Toxicol Sci       Date:  2013-11-09       Impact factor: 4.849

8.  A robotic BG1Luc reporter assay to detect estrogen receptor agonists.

Authors:  Matthew A Stoner; Chun Z Yang; George D Bittner
Journal:  Toxicol In Vitro       Date:  2014-04-18       Impact factor: 3.500

9.  Comparison between novel steroid-like and conventional nonsteroidal antioestrogens in inhibiting oestradiol- and IGF-I-induced proliferation of human breast cancer-derived cells.

Authors:  A de Cupis; D Noonan; P Pirani; A Ferrera; L Clerico; R E Favoni
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

10.  Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.

Authors:  G L Powers; S J Ellison-Zelski; A J Casa; A V Lee; E T Alarid
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.